BSG and malignant epithelial tumor of ovary: The mortality rates of patients with high expression of CD147 and HE4 were 52.9% (29/56) and 50.8% (33/65) in epithelial ovarian malignant tumors, respectively, which were significantly higher than that in CD147 low expression group (27.5%, [11/40]) and HE4 low expression group (22.6%, [7/31]).